Eli Lilly said Monday that its obesity pill Foundayo significantly reduced the severity of obstructive sleep apnea in patients with obesity, according to results from a late-stage trial. Obstructive sleep apnea is the most common sleep-related breathing disorder.
The company plans to file for U.S. approval of the daily pill for moderate-to-severe obstructive sleep apnea in adults with obesity or who are overweight. Lilly said it expects to submit the results to the Food and Drug Administration by the end of the year. Foundayo rolled out in the U.S. in April.
The trial tested Foundayo in two independent studies. The first included 363 patients who were unable or unwilling to use positive airway pressure, or PAP, therapy. The second included 349 people who were already using PAP therapy.
Among patients not using PAP therapy, those taking Foundayo had an average of 21.1 fewer apnea-hypopnea index events per hour at 52 weeks, compared with an average reduction of 4.8 per hour for placebo. Lilly said the overall reduction was 43.8%, compared with 6.3% for placebo. Among patients using PAP therapy, Foundayo led to an overall reduction of about 27.5%, compared with 3% for placebo.
Lilly said patients in both groups lost roughly 11% of their weight at 52 weeks. The company said the most common side effects were gastrointestinal, including nausea, diarrhea, constipation and vomiting, and were generally mild to moderate. About 12% of patients not using PAP therapy discontinued Foundayo due to side effects, compared with 3.8% on placebo.
Zepbound, another Lilly weight-loss injection, became the first medication approved in the U.S. for obstructive sleep apnea in December 2024.